CQAs and potency data required

Jessica Rose Sep 07, 2024 READ

Everybody knows that the COVID-19 shots are associated with harms. We know this from pharmacovigilance and hospital data, peer-reviewed studies and on-the-ground reports of everything from cancer to autoimmune conditions. The exact mechanism of action of harm has yet to be definitively defined, but we do know that the harms are comprehensive and this points to immune system dysfunction.

A question on everybody’s minds is this:

How did it come to pass that billions of people were subjected to experimental gene-based prophylactic prodrugs wrapped in lipid nanoparticles when a plethora of deficiencies in critical quality attributes (CQAs) and potency remain even today?

Perhaps an even more relevant question is this:

How can it be that self-amplifying RNA-LNP technology which is based on exactly the same principles as the COVID-LNP product platform – plus some – is about to be pushed onto the Japanese public when none of these CQAs or potencies have been mitigated or even acknowledged by the entities pushing them?